Insmed announces proposed $650 million public offering of common stock

Bridgewater, n.j. , june 11, 2025 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering.
INSM Ratings Summary
INSM Quant Ranking